Split into Three: Where Does DuPont’s Business Divestiture Gene Come From?

Upon completion of the above spin-offs, the 'new DuPont' will become the largest of the three independent publicly traded companies, with 2023 sales of $6.6 billion. The electronics business slated for separation generated $4 billion in revenue last year, while the water business brought in $1.5 billion. The electronics company will focus on 'semiconductor solutions and advanced electronics', comprising DuPont’s existing semiconductor technologies, interconnect solutions business, and electronics-related product lines from Industrial Solutions. In 2023, this business generated approximately $4 billion in sales, with an operating EBITDA margin of 29%—about 60% derived from semiconductor materials and 40% from interconnect materials. Its primary end markets include AI chips, digital displays, printed circuit boards, and consumer electronics. The water company will consist of DuPont’s current Water Solutions business and will operate as 'an integrated water treatment solutions provider', generating approximately $1.5 billion in sales in 2023, with an operating EBITDA margin of 24%. Its portfolio centers on advanced technologies in reverse osmosis, ion exchange, and ultrafiltration, serving applications across industrial water treatment, municipal water treatment, life sciences, and emerging technologies such as direct lithium extraction. The remaining businesses will stay within the 'new DuPont' corporate structure, organized into healthcare, mobility, safety, and protection. Net sales in 2023 totaled approximately $6.6 billion, with an operating EBITDA margin of 24%: safety and protection accounted for roughly half the sales—including building materials and brands such as Tyvek® and Kevlar®; the remainder was evenly split between mobility and healthcare, with key application areas including electric vehicle (EV) batteries, structural adhesives, biopharmaceuticals, and medical devices. DuPont stated that the separation plan will enable each newly independent company to tailor its capital allocation strategy to its own strategic growth objectives. The new entities will gain greater strategic flexibility to pursue mergers and acquisitions—activities designed to strengthen their respective portfolios and attract distinct investor interest. Concurrently with the announcement of the separation plan, DuPont also restructured its management team: current CFO Lori Koch was appointed CEO, succeeding Ed Breen, who will remain Executive Chairman. Antonella Franzen, currently CFO of DuPont Water & Protection, was named CFO. These appointments take effect June 1—clearly reflecting DuPont’s organizational realignment driven by the business separation and financial management priorities. Antonella Franzen (left); Ed Breen (center); Lori Koch (right)

DuPont™ Liveo™ Makes Its Debut at Medtec China 2026, Advancing Healthcare Development Through Localization Strategy and Product Innovation

Localization is merely one step along our ongoing innovation journey. As the medical device industry continuously advances toward higher performance, longer service life, and stricter safety standards, innovation in advanced materials has become a pivotal driver of industry progress. Recently, DuPont™ Liveo™ Pharmaceutical-Grade Ultra-Low-Temperature TPE Tubing received the 2026 R&D 100 Awards—the world’s premier recognition for technological innovation—further affirming DuPont’s leadership in biopharmaceutical process material innovation. Widely regarded as one of the most influential awards in global R&D, the R&D 100 Awards honor breakthrough technologies and products with transformative industry impact. Specifically engineered for ultra-low-temperature biopharmaceutical applications, DuPont™ Liveo™ Pharmaceutical-Grade Ultra-Low-Temperature TPE Tubing maintains exceptional flexibility and performance stability under extreme cryogenic conditions—helping customers address critical challenges across biopharmaceutical manufacturing, storage, and transportation. At this year’s Medtec China, DuPont™ Liveo™ unveiled two innovative products targeting long-term implantable and skin-contact medical device applications. Liveo™ Q7-88XX Series Liquid Silicone Rubber (LSR) is specially developed for long-term implantation (>29 days), offering outstanding biocompatibility, mechanical properties, and long-term stability—meeting the stringent reliability and durability requirements of implantable medical devices. For instance, it supports the exploration, development, and commercialization of implantable neuromodulation devices and medical-grade 'brain-computer interfaces', providing device manufacturers with a trusted material solution. Meanwhile, Liveo™ MG-2543 silicone elastomer delivers high transparency, low viscosity, excellent processability, and compliance with relevant medical biocompatibility testing standards—enabling greater design flexibility and process adaptability for medical device encapsulation, microneedle mold fabrication, IVD diagnostic consumables, protective coating for medical PCBs, potting of medical LED phototherapy devices, precision molding, and innovative device design. This helps customers accelerate product development and bring innovations to market faster. These newly launched products further enrich DuPont™ Liveo™’s portfolio of high-performance materials for healthcare, fully demonstrating the company’s steadfast commitment to advancing materials innovation and meeting the industry’s ever-evolving needs. Leveraging deep insights into medical device safety, reliability, and long-term performance, DuPont™ Liveo™ is dedicated to delivering more valuable material solutions—empowering next-generation medical product innovation and development. At the new product launch event, Dean Childers, Vice President and General Manager of DuPont Healthcare Solutions, remarked: 'China is one of the world’s most dynamic and innovative markets for healthcare and medical devices. In response to rapidly evolving market demands, DuPont™ Liveo™ continues to advance its localization strategy—strengthening local supply and service capabilities to respond more swiftly to customer needs. At the same time, we are significantly increasing investment in innovation, leveraging cutting-edge materials science and application development expertise to deliver novel products and solutions tailored to future medical applications.' From deepening localization to accelerating product innovation, DuPont™ Liveo™ consistently places customer needs and industry trends at the core—actively enhancing local supply and service capabilities while continuously expanding its portfolio of healthcare-focused materials.

How New Water Filters And AI Tools At DuPont (DD) Have Changed Its Investment Story

17 hours ago

DuPont expanded its water treatment portfolio with new Electrodeionization modules and partnered with Microsoft and NobleAI for AI in R&D. These initiatives aim to boost productivity and drive revenue growth in its Healthcare & Water Technologies segment by 2029.

Yahoo! Finance Canada

2026-04-02

DuPont completes aramids divestiture

2026-04-08

DuPont de Nemours Inc. Stock Outperforms Competitors on Strong Trading Day

2026-04-09

DuPont Expands Water Solutions With Inge UF Integrated Pre-Filter Modules

2026-04-09

DuPont Expands FilmTec™ Fortilife™ Portfolio for Advanced ZLD/MLD and Resource Recovery Applications

2026-04-14

DuPont Launches AmberChrom XT SL Chromatography Resins